Sudden Death in Patients With Coronary Heart Disease Without Severe Systolic Dysfunction

Area of Science:

• Cardiology
• Preventive Cardiology
• Clinical Research

Background:

• Sudden and/or arrhythmic death (SAD) is a significant concern in coronary heart disease (CHD) patients, particularly those without severe systolic dysfunction.
• Current strategies for preventing sudden death are limited in this specific patient population.
• Understanding competing causes of death is crucial for developing targeted prevention trials.

Purpose of the Study:

• To estimate the contemporary incidence of SAD versus other causes of death in CHD patients without severe systolic dysfunction.
• To identify high-risk subgroups within this population who could benefit from future SAD prevention strategies.
• To analyze the relationship between clinical risk factors and modes of death.

Main Methods:

• A prospective observational cohort study involving 5761 participants across 135 clinical sites in the US and Canada.
• Participants had coronary heart disease but did not meet criteria for primary prevention implantable cardioverter-defibrillator therapy (LVEF >35% or NYHA class I with LVEF >30%).
• Baseline clinical risk factors including age, left ventricular ejection fraction (LVEF), and New York Heart Association (NYHA) heart failure class were assessed.

Main Results:

• Over a median follow-up of 3.9 years, the cumulative incidence of SAD was 2.1% and non-SAD was 7.7%.
• SAD constituted 56% of cardiovascular deaths, but noncardiac death was the most common cause of overall mortality.
• Highest SAD incidence was observed in patients with LVEF 30%-40% (4.9%) and NYHA class III/IV heart failure (5.1%). Moderately reduced LVEF (40%-49%) was linked to higher SAD risk, while NYHA class II and older age were associated with non-SAD.

Conclusions:

• SAD accounts for a substantial proportion of mortality in contemporary CHD patients without severe systolic dysfunction.
• Left ventricular ejection fraction, age, and NYHA class are key factors differentiating SAD from non-SAD.
• Future risk stratification efforts must incorporate both absolute and proportional risks of SAD across diverse clinical subgroups.